ATLANTA, Aug. 27 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today announced the results of its Annual Shareholders Meeting, held on August 24, 2010.
During the meeting, shareholders re-elected seven nominees for directors of the company to serve until the 2011 Annual Meeting of Shareholders and until their successors are duly elected or appointed and qualified. They are:
Additionally, stockholders ratified the appointment of Porter Keadle Moore LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2010.
Don Hildebrand, company co-founder and Chairman of the Board of Directors, provided opening remarks and conducted the formal business of the meeting.
In addition to the business of the annual meeting, Robert McNally, president and chief executive officer, provided an overview of the company's progress, highlighting GeoVax's performance since the last annual meeting held in June 2009. He discussed significant scientific outreach including conferences where GeoVax participated in presenting advances in vaccine development, and improvement in corporate communications through a new public and investor relations firm, IRG. Dr. Harriet Robinson, company CSO, discussed clinical and research progress including the current status of the Phase 2a Preventative Vaccine Trial including the expansion from 225 to 300 part
|SOURCE GeoVax Labs, Inc.|
Copyright©2010 PR Newswire.
All rights reserved